Search results for "Hydroxyurea"

showing 10 items of 21 documents

Cardiovascular events and intensity of treatment in polycythemia vera.

2013

A b s t r ac t Background Current treatment recommendations for patients with polycythemia vera call for maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in a randomized clinical trial. Methods We randomly assigned 365 adults with JAK2-positive polycythemia vera who were being treated with phlebotomy, hydroxyurea, or both to receive either more intensive treatment (target hematocrit, <45%) (low-hematocrit group) or less intensive treatment (target hematocrit, 45 to 50%) (high-hematocrit group). The primary composite end point was the time until death from cardiovascular causes or major thrombotic events. The secondary end points were cardiovascula…

MaleHematocritRECURRENT THROMBOSISlaw.inventionAged; Antineoplastic Agents; Cardiovascular Diseases; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hydroxyurea; Janus Kinase 2; Male; Middle Aged; Polycythemia Vera; Thrombosis; Hematocrit; Phlebotomy; Medicine (all)LEUKOCYTOSISPolycythemia veraRandomized controlled trialPhlebotomylawhemic and lymphatic diseasesESSENTIAL THROMBOCYTHEMIAClinical endpointHydroxyureaPolycythemia Vera Secondary ProphylaxisESSENTIAL THROMBOCYTHEMIA RECURRENT THROMBOSIS RISK-FACTOR HEMATOCRIT MANAGEMENT LEUKOCYTOSIS PREVENTION DIAGNOSIS EFFICACY WARFARINPolycythemia Veramedicine.diagnostic_testMedicine (all)Hazard ratioGeneral MedicineMiddle AgedCombined Modality TherapyHematocritCardiovascular DiseasesFemalemedicine.medical_specialtyrandomized trial; polycythemia veraAntineoplastic AgentsCardiovascular eventDIAGNOSISWARFARINRISK-FACTORInternal medicineMANAGEMENTmedicineHumansMyelofibrosisAdverse effectAgedbusiness.industryThrombosisPhlebotomyJanus Kinase 2EFFICACYmedicine.diseasePREVENTIONSurgeryPolycythemia Vera Cardiovascular event hematocritSettore MED/15 - MALATTIE DEL SANGUEbusinessFollow-Up Studies
researchProduct

Hydroxyurea modulates 5-fluorouracil antineoplastic activity in advanced head and neck carcinoma pretreated with chemotherapy

1992

After informed consent 21 patients with advanced head and neck cancer resistant to folinic acid/5-fluorouracil (FA/5FU + cisplatin) were treated with weekly FA/5FU plus low dose hydroxyurea (HU) to evaluate if HU could further modulate 5FU antineoplastic activity. Five patients achieved a partial response (23.8%) which was short-lived (mean duration 6.5 months). Three patients (14%) had stable disease and 13 (62%) progressed. Among responders, four patients had epidermoidal carcinoma and one had clear cell carcinoma. Treatment was well tolerated and 5FU-related toxicity was not apparently worsened by the addition of HU. The most frequent toxicities were nausea/vomiting (81%), diarrhea (52%)…

MaleOncologyCancer Researchmedicine.medical_specialtyNauseamedicine.medical_treatmentGastroenterologyDrug Administration ScheduleFolinic acidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansHydroxyureaPharmacology (medical)AgedAged 80 and overPharmacologyChemotherapyLeukopeniabusiness.industryMiddle Agedmedicine.diseaseSurvival RateOncologyHead and Neck NeoplasmsFluorouracilClear cell carcinomaVomitingFemaleFluorouracilmedicine.symptombusinessmedicine.drugAnti-Cancer Drugs
researchProduct

Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy

2008

Abstract Objective: To analyse the effect of hydroxyurea (HU) on the JAK2-V617F allelic ratio (%JAK2-V617F) of patients with Polycythaemia Vera (PV) and Essential Thrombocythaemia (ET). Methods: Thirty-six patients were examined sequentially prior to and after on-set of (HU) therapy (8 PV, 17 ET), or while remaining untreated (2 PV, 9 ET). For all patients, the %JAK2-V617F was determined in purified blood granulocytes using sensitive allele-specific, quantitative PCRs. In a second study, two distinct groups of patients were examined at a single time point at the time of diagnosis (99 PV, 178 ET) or while receiving HU (36 PV, 98 ET). Results: HU therapy (median duration: 15 months) reduced t…

MalePediatricsmedicine.medical_specialtymedicine.drug_classImmunologyClone (cell biology)Allelic ratioBiochemistryAntimetaboliteGastroenterologyCohort StudiesHydroxycarbamidePolycythemia veraAntisickling Agentshemic and lymphatic diseasesInternal medicinemedicineHumansHydroxyureaProspective cohort studyPolycythemia VeraMyeloproliferative neoplasmAgedDNA PrimersRetrospective StudiesAged 80 and overJanus kinase 2HematologybiologyEssential thrombocythemiabusiness.industryCell BiologyHematologyJanus Kinase 2Middle Agedmedicine.diseaseSurgeryAmino Acid SubstitutionMutationbiology.proteinFemalebusinessGranulocytesThrombocythemia Essentialmedicine.drugHaematologica
researchProduct

Mushroom bodies enhance initial motor activity in Drosophila.

2009

The central body (or central complex, CCX) and the mushroom bodies (MBs) are brain structures in most insect phyla that have been shown to influence aspects of locomotion. The CCX regulates motor coordination and enhances activity while MBs have, thus far, been shown to suppress motor activity levels measured over time intervals ranging from hours to weeks. In this report, we investigate MB involvement in motor behavior during the initial stages (15 minutes) of walking in Buridan's paradigm. We measured aspects of walking in flies that had MB lesions induced by mutations in six different genes and by chemical ablation. All tested flies were later examined histologically to assess MB neuroan…

Malemedia_common.quotation_subjectMutantChemical ablationInsectMotor ActivityCellular and Molecular NeuroscienceOrientationGeneticsmedicineAnimalsHydroxyureaMotor activityDrosophilaMushroom Bodiesmedia_commonbiologyfungiBrainbiology.organism_classificationMotor coordinationCell biologymedicine.anatomical_structurePhenotypeMushroom bodiesMutationDrosophilaFemaleNeurosciencePhotic StimulationNeuroanatomyJournal of neurogenetics
researchProduct

Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms

2009

The evidence that leukocytes may contribute to the pathogenesis of thrombosis in Chronic Myeloproliferative Neoplasms is increasing but not definitive. To further enforces whether an increased leukocyte count is associated with thrombosis and whether this effect can be modulated by cytoreductive therapy, we analyzed the clinical course of 187 patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) followed at two Italian Institutions over a period of 7 years. The association was measured at diagnosis or before thrombotic events: a multivariable analysis was carried out using data at baseline and time-dependent covariates. We found that white blood cells (WBC) count above 9.5…

Malemedicine.medical_specialtyPathologyLeukocytosismyeloproliferative neoplasm thrombosis jak2GastroenterologyLeukemia Myeloid Chronic Atypical BCR-ABL NegativeSettore MED/15 - Malattie Del SangueLeukocyte CountPolycythemia verahemic and lymphatic diseasesInternal medicinemedicineHumansHydroxyureaLeukocytosisRisk factorProspective cohort studyPolycythemia VeraMyeloproliferative neoplasmAgedbusiness.industryEssential thrombocythemiaHazard ratioThrombosisHematologyGeneral MedicineJanus Kinase 2Middle Agedmedicine.diseaseThrombosisMultivariate AnalysisFemalemedicine.symptombusinessThrombocythemia Essential
researchProduct

Flow cytometry, sorting and immunocharacterization with proliferating cell nuclear antigen of cycling and non-cycling cells in synchronized pea root …

1997

In the 3-d-old 2-mm root tip of Pisum sativum L. cv. Lincoln the percentage of actively proliferating cells is estimated to be 70%. The remaining cells are non-cycling and arrested with 2C and 4C DNA content in G0 and in G2Q, respectively. In this work we studied the kinetic significance of these quiescent cells, using the sorting capabilities of flow cytometry and immunofluorescence techniques to detect the proliferation marker PCNA (proliferating cell nuclear antigen) inside cells within the different cell-cycle compartments. While in animal cells, PCNA is present at a high level only in actively proliferating cells, in 3-d-old pea root tips 95% of the cells are PCNA-positive. After flow …

MeristemPlant ScienceBiologyImmunofluorescencePlant RootsPisumFlow cytometryProliferating Cell Nuclear AntigenGeneticsmedicineHydroxyureaProliferation MarkerFluorescent Antibody Technique IndirectRoot capCell Nucleusmedicine.diagnostic_testCell CyclePeasMicrotomyCell cycleMeristemFlow Cytometrybiology.organism_classificationProliferating cell nuclear antigenCell biologybiology.proteinPlanta
researchProduct

Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyur…

1996

BACKGROUND To date there is no established chemotherapeutic treatment for patients with unresectable locally advanced and/or metastatic carcinomas of the exocrine pancreas or the gallbladder. A multicenter Phase II trial has been performed by the Southern Italy Oncology Group with the aim of evaluating the clinical effectiveness and tolerability of weekly 5-fluorouracil (5-FU) in modulation with intravenous (i.v.) high dose levofolinic acid and oral hydroxyurea. METHODS A total of 70 patients fulfilling the standard eligibility for a Phase II study were enrolled in the trial. Forty patients had advanced pancreatic adenocarcinoma and 30 had advanced gallbladder carcinoma. The treatment sched…

OncologyMaleCancer Researchmedicine.medical_specialtyAntimetabolites AntineoplasticPancreatic diseaseAntidotesLeucovorinPhases of clinical researchAdministration OralAntineoplastic AgentsAdenocarcinomaGastroenterologyDrug Administration ScheduleMetastatic carcinomaInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansHydroxyureaInfusions IntravenousAgedbusiness.industryGallbladderCarcinomaRemission InductionLeukopeniaMiddle Agedmedicine.diseasePancreatic NeoplasmsSurvival Ratemedicine.anatomical_structureOncologyTolerabilityItalyInjections IntravenousDisease ProgressionAdenocarcinomaFemaleGallbladder NeoplasmsFluorouracilbusinessProgressive diseaseCancer
researchProduct

Development of polymer-based nanoparticles for Zileuton delivery to the lung : PMeOx and PMeOzi surface chemistry reduces interactions with mucins

2021

In this paper, two amphiphilic graft copolymers were synthesized by grafting polylactic acid (PLA) as hydrophobic chain and poly(2-methyl-2-oxazoline) (PMeOx) or poly(2-methyl-2-oxazine) (PMeOzi) as hydrophilic chain, respectively, to a backbone of α,β-poly(N-2-hydroxyethyl)-D,L-aspartamide (PHEA). These original graft copolymers were used to prepare nanoparticles delivering Zileuton in inhalation therapy. Among various tested methods, direct nanoprecipitation proved to be the best technique to prepare nanoparticles with the smallest dimensions, the narrowest dimensional distribution and a spherical shape. To overcome the size limitations for administration by inhalation, the nano-into-micr…

Poly(2-oxazoline)sPolymers116 Chemical sciencesPharmaceutical ScienceMedicine (miscellaneous)Nanoparticle02 engineering and technology01 natural scienceschemistry.chemical_compoundDrug Delivery SystemsNanoparticlePolylactic acidCopolymerPolyaminesHydroxyureaGeneral Materials SciencePoly(2-oxazine)sDRUG-DELIVERYCells Culturedchemistry.chemical_classificationDrug CarriersCHALLENGESAIRWAY MUCUSPolymer021001 nanoscience & nanotechnologyGraftingDIFFUSIONPolyaspartamidePULMONARY DELIVERYDrug deliveryMolecular Medicine0210 nano-technologyHydrophobic and Hydrophilic Interactionsmedicine.drugLung inflammationPolyestersBiomedical EngineeringINHIBITIONBioengineeringBronchi010402 general chemistryPolylactic acidZileutonAmphiphileAdministration InhalationmedicineHumansPoly(2-oxazoline)RELEASEMucinsBronchial DiseasesEpithelial CellsZileuton0104 chemical scienceschemistryChemical engineeringSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoNanoparticlesASTHMAPoly(2-oxazine)
researchProduct

Functional Connection Between the Clb5 Cyclin, the Protein Kinase C Pathway and the Swi4 Transcription Factor in Saccharomyces cerevisiae

2005

Abstract The rsf12 mutation was isolated in a synthetic lethal screen for genes functionally interacting with Swi4. RSF12 is CLB5. The clb5 swi4 mutant cells arrest at G2/M due to the activation of the DNA-damage checkpoint. Defects in DNA integrity was confirmed by the increased rates of chromosome loss and mitotic recombination. Other results suggest the presence of additional defects related to morphogenesis. Interestingly, genes of the PKC pathway rescue the growth defect of clb5 swi4, and pkc1 and slt2 mutations are synthetic lethal with clb5, pointing to a connection between Clb5, the PKC pathway, and Swi4. Different observations suggest that like Clb5, the PKC pathway and Swi4 are in…

Saccharomyces cerevisiae ProteinsMitotic crossoverBlotting WesternMutantSaccharomyces cerevisiaeSaccharomyces cerevisiaeInvestigationsCyclin BBiologymedicine.disease_causeGeneticsmedicineHydroxyureaImmunoprecipitationDNA FungalFluorescent Antibody Technique IndirectTranscription factorProtein Kinase CProtein kinase CCyclinRecombination GeneticGeneticsMutationKinaseCell CyclefungiFlow Cytometrybiology.organism_classificationMolecular biologyCell biologyDNA-Binding ProteinsMutationChromosomes FungalTranscription FactorsGenetics
researchProduct

The molecular structure of N-hydroxyurea

1996

Ab initio calculations were performed on the tautomers and conformers of N-hydroxyurea using a 6-31G** basis set. The minimum-energy structures have been found and the importance of the intramolecular hydrogen bond as the stabilizing factor was pointed out. © 1996 John Wiley &amp; Sons, Inc.

Settore CHIM/03 - Chimica Generale E Inorganicaab initio calculationsmolecular structureN-hydroxyurea
researchProduct